Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients

* Male or female aged ≥ 20 years or adult age as per local regulations, at time of informed consent

* Histologically or cytologically confirmed advanced solid tumor (Part 1) or NSCLC with HER2 mutations as determined by the central result (Part 2)

* For patients in Part 2 only: Patients has measurable disease per RECIST 1.1 criteria

* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Part 1), 0 to 2 (Part 2)

* Appropriate candidate for experimental therapy

* Adequate organ function

* Known active or untreated central nervous system (CNS) metastases and/or carcinomatous meningitis

* For patients in Part 2 only: Previously treated with EGFR or HER2 TKIs.

* Serious acute or chronic infections

* Received a live-virus vaccination

* Received prior anticancer or other investigational therapy within 28 days or 5× the half-life prior to the first dose.

* Not recovered from prior- treatment toxicities to Grade ≤1

* Major surgery within 28 days prior to the study treatment

* Concurrent malignancy within 2 years prior to first dose

* History or presence of clinically relevant cardiovascular abnormalities. QTcF ≥ 470 ms

* Significant gastrointestinal disorder(s) that could interfere with absorption of ABT101

* Known to have a history of alcoholism or drug abuse